BIOMAT Database Logo BIOMAT Database Logo

Phase II trial of mitoxantrone in advanced sarcomas: a Southwest Oncology Group study. 1985

F E Bull, and D D Von Hoff, and S P Balcerzak, and R L Stephens, and F J Panettiere

UI MeSH Term Description Entries
D007263 Infusions, Parenteral The administration of liquid medication, nutrient, or other fluid through some other route than the alimentary canal, usually over minutes or hours, either by gravity flow or often by infusion pumping. Intra-Abdominal Infusions,Intraperitoneal Infusions,Parenteral Infusions,Peritoneal Infusions,Infusion, Intra-Abdominal,Infusion, Intraperitoneal,Infusion, Parenteral,Infusion, Peritoneal,Infusions, Intra-Abdominal,Infusions, Intraperitoneal,Infusions, Peritoneal,Intra Abdominal Infusions,Intra-Abdominal Infusion,Intraperitoneal Infusion,Parenteral Infusion,Peritoneal Infusion
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008942 Mitoxantrone An anthracenedione-derived antineoplastic agent. Mitozantrone,CL-232325,DHAQ,Mitoxantrone Acetate,Mitoxantrone Hydrochloride,Mitroxone,NSC-279836,NSC-287836,NSC-299195,NSC-301739,NSC-301739D,Novantron,Novantrone,Onkotrone,Pralifan,Ralenova,Acetate, Mitoxantrone,CL 232325,CL232325,Hydrochloride, Mitoxantrone,NSC 279836,NSC 287836,NSC 299195,NSC 301739,NSC 301739D,NSC279836,NSC287836,NSC299195,NSC301739,NSC301739D
D001859 Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES. Bone Cancer,Cancer of Bone,Cancer of the Bone,Neoplasms, Bone,Bone Neoplasm,Neoplasm, Bone
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006333 Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION. Cardiac Failure,Heart Decompensation,Congestive Heart Failure,Heart Failure, Congestive,Heart Failure, Left-Sided,Heart Failure, Right-Sided,Left-Sided Heart Failure,Myocardial Failure,Right-Sided Heart Failure,Decompensation, Heart,Heart Failure, Left Sided,Heart Failure, Right Sided,Left Sided Heart Failure,Right Sided Heart Failure

Related Publications

F E Bull, and D D Von Hoff, and S P Balcerzak, and R L Stephens, and F J Panettiere
Phase II trial of echinomycin in advanced soft tissue sarcomas. A Southwest Oncology Group study.
November 1990, Investigational new drugs,
F E Bull, and D D Von Hoff, and S P Balcerzak, and R L Stephens, and F J Panettiere
Mitoxantrone in advanced breast cancer: a phase II trial of the Southwest Oncology Group.
January 1983, Investigational new drugs,
F E Bull, and D D Von Hoff, and S P Balcerzak, and R L Stephens, and F J Panettiere
Phase II trial of mitoxantrone in multiple myeloma: a Southwest Oncology Group Study.
November 1985, Cancer treatment reports,
F E Bull, and D D Von Hoff, and S P Balcerzak, and R L Stephens, and F J Panettiere
Phase II evaluation of mitoxantrone in advanced pancreatic carcinoma: a Southwest Oncology Group study.
February 1990, Investigational new drugs,
F E Bull, and D D Von Hoff, and S P Balcerzak, and R L Stephens, and F J Panettiere
Phase II trial of dianhydrogalactitol in advanced soft tissue and bony sarcomas: a Southwest Oncology Group study.
April 1979, Cancer treatment reports,
F E Bull, and D D Von Hoff, and S P Balcerzak, and R L Stephens, and F J Panettiere
Phase II clinical trial of mitoxantrone in patients with advanced renal cell carcinoma: a Southwest Oncology Group study.
June 1984, Cancer treatment reports,
F E Bull, and D D Von Hoff, and S P Balcerzak, and R L Stephens, and F J Panettiere
Phase II trial of piroxantrone for advanced or metastatic soft tissue sarcomas. A Southwest Oncology Group study.
November 1993, Investigational new drugs,
F E Bull, and D D Von Hoff, and S P Balcerzak, and R L Stephens, and F J Panettiere
A phase II trial of paclitaxel in patients with advanced soft tissue sarcomas. A Southwest Oncology Group study.
December 1995, Cancer,
F E Bull, and D D Von Hoff, and S P Balcerzak, and R L Stephens, and F J Panettiere
Phase II trial of amonafide in advanced colorectal cancer: a SouthWest Oncology Group study.
February 1993, Anti-cancer drugs,
F E Bull, and D D Von Hoff, and S P Balcerzak, and R L Stephens, and F J Panettiere
Phase II trial of topotecan in advanced gastric cancer: a Southwest Oncology Group study.
January 1997, Investigational new drugs,
Copied contents to your clipboard!